Floatz Rating
B62/100
Confidence
Indicative
Sponsor
GlaxoSmithKline
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07286266CT.gov A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) | — | Not Yet Recruiting | — | — | — |
NCT06885697CT.gov Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma | — | Recruiting | — | — | — |
NCT06305299CT.gov Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells | — | Recruiting | — | — | — |
NCT06400472CT.gov A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05451849CT.gov A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | — | Active Not Recruiting | — | — | — |
NCT05194072CT.gov A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05007106CT.gov MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | — | Completed | — | — | — |
NCT04956640CT.gov Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | — | Active Not Recruiting | — | — | — |
NCT04519151CT.gov Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer | — | Recruiting | — | — | — |
NCT04660929CT.gov CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | — | Unknown | — | — | — |
Show 6 more trialsShow fewer
NCT04561362CT.gov Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | — | Active Not Recruiting | — | — | — |
NCT04389632CT.gov A Study of Sigvotatug Vedotin in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT03012620CT.gov Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types | — | Completed | — | — | — |
NCT02674061CT.gov Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) | — | Completed | — | — | — |
NCT02499952CT.gov Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors | — | Terminated | — | — | — |
NCT00001426CT.gov A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | GlaxoSmithKline | P3 | B · 62 |
| Adriamycin | GlaxoSmithKline | P4 | BBB |
| Carboplatin | Eli Lilly and Company | P3 | BB |
| Pazopanib | The Christie NHS Foundation Trust | P2 | BB |
| Canfosfamide | Telik | P3 | BB |
| Niraparib | GlaxoSmithKline | P4 | BB |
| Docetaxel | Merck Sharp & Dohme LLC | P2 | BB |
| Nogitecan | GlaxoSmithKline | P3 | B |
| Trabectedin | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P3 | B |
+42 more in the Ovarian Neoplasm cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Ovarian Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-ovarian-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →